| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2144226 | Lung Cancer | 2006 | 7 Pages |
Abstract
Oral gefitinib, as compared to conventional chemotherapy, has comparable effect but less toxicity as a first-line treatment in Chinese patients who have advanced NSCLC, especially in those with adenocarcinoma histology. A further phase III prospective study comparing gefitinib to standard chemotherapy to define the efficacy of gefitinib is appropriate in advanced NSCLC patients.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Wei-Chun Lin, Chao-Hua Chiu, Jia-Ling Liou, Yuh-Min Chen, Reury-Perng Perng, Chun-Ming Tsai,